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Development of an optimized AAV2/5 gene therapy vector for
Leber congenital amaurosis owing to defects in RPE65
A Georgiadis1, Y Duran1, J Ribeiro1, L Abelleira-Hervas1, SJ Robbie1, B Sünkel-Laing1, S Fourali1, A Gonzalez-Cordero1, E Cristante1,
M Michaelides1,2, JWB Bainbridge1,2, AJ Smith1 and RR Ali1,2
Leber congenital amaurosis is a group of inherited retinal dystrophies that cause severe sight impairment in childhood; RPE65-
deﬁciency causes impaired rod photoreceptor function from birth and progressive impairment of cone photoreceptor function
associated with retinal degeneration. In animal models of RPE65 deﬁciency, subretinal injection of recombinant adeno-associated
virus (AAV) 2/2 vectors carrying RPE65 cDNA improves rod photoreceptor function, and intervention at an early stage of disease
provides sustained beneﬁt by protecting cone photoreceptors against retinal degeneration. In affected humans, administration of
these vectors has resulted to date in relatively modest improvements in photoreceptor function, even when retinal degeneration is
comparatively mild, and the duration of beneﬁt is limited by progressive retinal degeneration. We conclude that the demand for
RPE65 in humans is not fully met by current vectors, and predict that a more powerful vector will provide more durable beneﬁt.
With this aim we have modiﬁed the original AAV2/2 vector to generate AAV2/5-OPTIRPE65. The new conﬁguration consists of an
AAV vector serotype 5 carrying an optimized hRPE65 promoter and a codon-optimized hRPE65 gene. In mice, AAV2/5-OPTIRPE65 is
at least 300-fold more potent than our original AAV2/2 vector.
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INTRODUCTION
Leber congenital amaurosis (LCA) is a group of inherited retinal
dystrophies that cause severe sight impairment in childhood.1
Mutations in the gene encoding the 65 kDa retinal pigment
epithelium–speciﬁc retinoid isomerase (RPE65) (locus name LCA2;
OMIM #204100) are responsible in upto 10% of affected
individuals. The encoded retinoid isomerase converts all-trans
retinyl ester to 11-cis retinal, which is critical for regeneration of
visual pigment in rod photoreceptor cells following exposure to
light. RPE65 deﬁciency causes severe dysfunction of rod photo-
receptor cells, which are wholly reliant on retinal pigment
epithelium–derived RPE65, resulting in severely impaired night
vision from birth. The function of cone photoreceptor cells, which
mediate daylight vision, colour discrimination and high visual
acuity, is relatively preserved in childhood because cones have
access to an alternative source of 11-cis retinal.2 However,
progressive degeneration of the outer retina associated with local
accumulation of toxic retinyl esters3 results in progressively severe
impairment of cone photoreceptor-mediated daylight vision by
early adulthood.
In animal models of Rpe65 deﬁciency, delivery of RPE65 cDNA
using recombinant AAV2/2 vectors injected subretinally mediates
dose-dependent improvements in retinal and visual function, as
assessed by electroretinography (ERG) and vision-guided
behaviour4–6 respectively. When administered at an early stage
of disease, protection against retinal degeneration results in
sustained beneﬁt in mice and dogs.4,7 In humans, gene-
augmentation therapy for RPE65 deﬁciency using AAV2/2 vectors
can improve aspects of sight.8–12 However, improvements in
photoreceptor function in humans have been relatively modest
compared with those in animal models, even when retinal
degeneration is relatively mild. Moreover, the duration of beneﬁt
to retinal sensitivity is limited by progressive retinal
degeneration.6,13,14 Reports of more stable improvements in
visual function have been based on the more subjective outcome
measures of visual acuity, Goldmann perimetry and navigational
vision) and pupilometry that is quantitative over only a limited
range. We have found that RPE65 expression in humans is greater
than that in dogs,8 indicating a higher demand for RPE65 protein
in the human retina. We conclude that the demand for RPE65
protein in humans is not fully met by current vectors and that
greater, more durable beneﬁt requires greater provision of RPE65
at an appropriately early point in disease progression.
Although intraocular administration of our original vector
rAAV2/2.hRPE65p.hRPE65 (AAV2/2-hRPE65) was generally well
tolerated in humans, a minority of participants receiving the
higher dose of 1012 viral genomes (vg) developed transient
intraocular inﬂammation with immune responses to AAV2
indicating dose-limiting toxicity.8 With the aim of enhancing
provision of RPE65 protein without exceeding the maximum
tolerated vector dose we have modiﬁed our original rAAV2/2
vector to increase the efﬁciency of transduction, transcription and
translation. Speciﬁcally, this included optimisation of the promoter
sequence, inclusion of an exogenous intron, optimisation of the
Kozak sequence, and codon optimisation of RPE65 sequence. We
selected an AAV2/5 vector because AAV2/5 vectors are more
effective than AAV2/2 vectors for gene delivery to human RPE cells
in vitro. In mice, the optimized vector AAV2/5-OPTIRPE65 improves
retinal function with at least 300-fold greater potency. We
hypothesize that, in humans affected by LCA2, AAV2/5-OPTIRPE65
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will provide higher levels of RPE65 protein than AAV2/2-hRPE65,
leading to greater and more sustained beneﬁt.
RESULTS AND DISCUSSION
To enhance the speciﬁcity and efﬁciency of expression we
modiﬁed the hRPE65 promoter by excising inhibitory elements
of the promoter using naturally occurring restriction enzyme sites.
We generated a range of fragment sizes based on the original
hRPE65 promoter and selected a fragment from position − 742 to
+15 relative to the transcription start site. Following subretinal
injection of AAV2/8 vectors into wild-type (WT) mice, we found
that the optimized promoter (NA65p) led to a marked increase in
expression of green ﬂuorescent protein (GFP) in RPE cells
(Figure 1), compared with the original promoter (hRPE65p).
Furthermore, the optimized NA65p promoter conferred substan-
tially greater speciﬁcity of expression for RPE cells, with no
evidence of ectopic expression in photoreceptor cells (Figure 1).
Comparison of GFP expression in the RPE driven by NA65p with
that of the constitutive promoter CBA (or CAG) in mice in vivo was
performed, following dissection of RPE/choroid from injected eyes
and demonstrated signiﬁcantly higher GFP messengerRNA
(mRNA) levels driven by NA65p (Po0.001; Supplementary
Figure S2). To conﬁrm that the NA65p promoter drives expression
in human cells we transduced RPE cells derived from human
induced pluripotent stem (iPS cells) using AAV2/5-NA65p.GFP.
Robust GFP ﬂuorescence provided evidence of efﬁcient AAV2/5-
NA65p mediated expression in human cells expressing markers of
differentiated RPE (Figures 2a and b). As AAV2/2 has proven to be
a relatively inefﬁcient serotype in various tissues, we compared
the abilities of AAV2/2-CMV.GFP and AAV2/5-CMV.GFP to trans-
duce human iPS cell derived RPE cells in vitro. The proportion of
RPE cells positive for GFP was almost 4-fold greater after
transduction with AAV2/5 (Figure 2c; Supplementary Figure S3
for representative images). Although this did not quite reach
signiﬁcance (P= 0.058) it indicated that AAV2/5 was likely to be a
more effective serotype for the transduction of human RPE.
To enhance protein translation in human cells we generated an
optimized cDNA sequence for the hRPE65 transgene exploiting
the degeneracy of the genetic code; intracellular availability of
transfer ribonucleic acids speciﬁc for each amino acid varies, and
optimising the RPE65 coding sequence in favour of transfer
ribonucleic acids that are more abundant in human cells can
promote RPE65 protein translation in humans.15 We replaced 7
rare codons (including a pair in tandem), a cryptic splice site, 4
cryptic premature polyadenylation sites and a direct repeat of 50
basepairs, and we improved the codon usage frequency. To
optimize gene expression further, we introduced an SV40 intron
and an optimized Kozak sequence between the promoter and the
hRPE65 gene (Supplementary Figure S1). We compared the
translation efﬁcacy of the codon-optimized RPE65 (OPTIRPE65)
gene with the wild-type RPE65 gene in vitro in human (HEK 293 T)
and murine (3T3) cells by plasmid transfection, using a
cytomegalovirus (CMV) promoter in each case since the human
RPE65 promoter is not active in these cell lines. Although no more
efﬁcient in murine 3T3 cells, in human HEK293T cells the
OPTIRPE65 plasmid mediated signiﬁcantly greater RPE65 protein
production than the original RPE65 coding sequence as assessed
by optical density measurements on western blots of whole cell
lysates (OPTIRPE65 5.6 ± 1.4 arbitrary units, hRPE65 0.79 ± 0.039
arbitrary units, P= 0.04; Figure 3). The increase in RPE65 protein
production is not solely based on the codon optimisation of the
RPE65 gene but also on the inclusion of the SV40 intron and Kozak
sequence. The optimized plasmid construct provided improved
mRNA stability and processing in human RPE cells in vitro,
resulting in 2.5-fold greater levels of mRNA (Supplementary
Figure S4). Since the impact of codon optimization for human
tRNA is not evident in the murine cells the expression of the
optimized construct in mice is likely to underestimate its potential
efﬁciency of expression in humans.
To increase the efﬁciency of RPE cell transduction we packaged
OPTIRPE65 into an AAV2/5 serotype vector and compared the
effect of the optimized vector (AAV2/5-OPTIRPE65) with that of
the original vector (AAV2/2-hRPE65) on electroretinography in the
mouse model for LCA2 (Rpe65− /−). AAV2/5-OPTIRPE65 was tested
at a concentration range of 3 × 107 to 1 × 1012 vg per mL. AAV2/2-
hRPE65 was tested at 1 × 1010 to 1 × 1012 vg per mL as
concentrations lower than 1 × 1010 vg per mL showed no evidence
of beneﬁt Subretinal administration of AAV2/5-OPTIRPE65 at a
300-fold dilution resulted in mean scotopic b-wave responses at 6-
weeks as great as, or greater than, responses following adminis-
tration of the original vector (Figure 4). The ERG improvement
achieved with AAV2/5-OPTIRPE65 at the 1 × 109 concentration
seems to reach a plateau of rescuable retinal function in the LCA2
mouse model, as similar levels of response were observed after
administration at a titre of 1 × 1012 vg per mL (average amplitude
97± 13 μV; Figure 4). WT mouse scotopic b-wave responses at a
similar age are measured at 180–200 μV. This ﬁnding demon-
strates that AAV2/5-OPTIRPE65 is at least 300-fold more potent
than AAV2/2-hRPE65 in restoring rod photoreceptor responses to
light stimulation. The potency of AAV2/5-OPTIRPE65 also com-
pares favourably against AAV2/2.CBA vectors in RPE65-deﬁcient
mice: while AAV2/5-OPTIRPE65 at a dose of 4 × 106 vg leads
reliably to improved b-wave amplitudes (average amplitude
91± 9 μV; Figure 4), published data suggest AAV2/2.CBA vectors
at a dose of 1 × 109 vg offer a less robust beneﬁt (improvements in
4 out of 10 animals; average b-wave amplitude of 60 μV).16 The
enhanced beneﬁt of AAV2/5-OPTIRPE65 to retinal function is the
consequence of the more rapid transduction kinetics of the
AAV2/5 serotype and improved mRNA stability owing to inclusion
of the intron in the optimized gene cassette. As previously noted,
the assessment in mice does not reﬂect the additional advantage
of codon optimisation for protein translation in human cells
Figure 1. Optimized promoter (NA65p) drives expression of GFP
with greater efﬁciency and with higher speciﬁcity for RPE cells.
Representative GFP ﬂuorescence in retinal cryosections of mice
4 weeks following subretinal injection of AAV2/8-hRPE65.GFP (a) or
AAV2/8-NA65p.GFP (b). 4′,6-diamidino-2-phenylindole was used to
visualize nuclei. GFP and merged images are shown for both panels.
INL, inner nuclear layer; outer nuclear layer; RPE. Viral dose: 4 × 109
vg/eye, n= 3. Scale bar, 60 μm.
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speciﬁcally, which confers no such advantage in mouse cells
(Figure 3).
To compare the production of OPTIRPE65 mRNA from AAV2/5-
OPTIRPE65 and hRPE65 mRNA from AAV2/2-hRPE65 with endo-
genous mouse Rpe65 (mRpe65) mRNA, we performed absolute
quantiﬁcation using quantitative real-time PCR (qPCR) in retinal
lysates of WT animals 6 weeks following intraocular vector
administration at a dose of 4 × 109 vg per eye (1 × 1012 vg per
mL). Total cDNA was prepared from retinal lysates and the number
of OPTIRPE65, human RPE65 and murine Rpe65 transcript
molecules was measured in 100 ng. We found no signiﬁcant
difference between the number of OPTIRPE65 and endogenous
murine Rpe65 transcripts (Figure 5). In contrast, AAV2/5-
OPTIRPE65 produced 4100-fold greater number of transcripts
than AAV2/2-hRPE65 (Po0.05). This ﬁnding indicates that in mice
in vivo the OPTIRPE65 expression cassette can mediate mRNA
expression similar to the physiological levels of the murine
Rpe65 gene.
To investigate the safety of long-term overproduction of RPE65
protein we measured retinal function and retinal thickness
9 months following subretinal administration of AAV2/5-
OPTIRPE65 at a dose of 4 × 109 vg per eye (1 × 1012 vg per mL)
in young adult WT mice and 8 weeks after administration of
2 × 1011 vg per eye (1 × 1012 vg per mL) in young adult rabbits
(Figure 6). This dose in mice is 1000-fold higher than the dose
required for a restoration of electrophysiological responses in
Figure 2. Transduction of human iPS-derived RPE cells with AAV2/5 vectors. RPE cells derived from human induced pluripotent stem (iPS) cells
were transduced using AAV2/5-NA65p.GFP. Phalloidin (a) and ZO-1 (b) staining was used to visualize individual cells in the cultured RPE
monolayer. 4′,6-diamidino-2-phenylindole was used to visualize nuclei. Light ﬁeld, merged and merged without nuclear stain images are
shown for both panels. Scale bar, 25 μm. (c) Comparison of human iPS-derived RPE transduction efﬁciencies of AAV2/2-CMV.GFP and AAV2/5-
CMV.GFP suggests AAV2/5 more efﬁciently transduces human RPE cells, although the difference just failed to reach signiﬁcance (P= 0.058;
mean± s.e.m.; n= 3).
Figure 3. In vitro RPE65 protein production following transfection of human (293 T) and murine (3T3) cells with plasmids carrying wild-type
hRPE65 cDNA or codon-optimized hRPE65 cDNA with SV40 intron. Western blot of whole cell lysates following transfection of pD10/CMV.
hRPE65 plasmid (hRPE65) or pD10/CMV.OPTIRPE65 (OPTIRPE65) plasmid in human and mouse cells. 293 T and 3T3 cell lines were transfected
with equal amounts of either pD10/CMV.hRPE65 or pD10/CMV.OPTIRPE65 plasmid and 10 μg of whole cell lysates were used for
immunoblotting with a human RPE65 antibody (RPE65). Histone 2B (H2B) was used as a loading control. Quantiﬁcation of RPE65 protein band
intensities and comparison between hRPE65 and OPTIRPE65 for both 293 T and 3T3 cell lines. (P= 0.04; mean± s.d.; n= 2).
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RPE65-deﬁcient mice. Furthermore, the vector-mediated expres-
sion of human RPE65 protein is superimposed on the normal
endogenous expression of mouse Rpe65 protein in WT animals.
No signiﬁcant difference in mean rod-mediated and cone
mediated b-wave amplitudes was evident at 9 months in mice
and at 8 weeks in rabbits (Figures 6a and d). On histological
examination, we measured no difference in outer nuclear layer
thickness in sections through the optic nerve, and observed
normal preservation of retinal layering and photoreceptor nuclei
(Figures 6b, c, e and f). We conclude that overexpression of RPE65
protein in the mouse and rabbit RPE is well tolerated.
Having identiﬁed evidence of systemic immune responses
against AAV2/2 capsid and intraocular inﬂammation in a small
minority of human participants following intraocular vector
administration, we have since optimized our AAV manufacturing
protocols to reduce the proportion of empty vector particles from
80 to 10%. The removal of empty vector particles is expected to
minimize immune responses and preserve the availability of cell
surface receptors for binding by ﬁlled vector particles. Since we
found that exposure of OPTIRPE65 vector to the surfaces of the
delivery syringe or cannula leads to no substantial reduction of the
effective dose in RPE65-deﬁcient mice, we have chosen not to
supplement the recipients with a surfactant, as has been
described by others.9
The surgical technique for vector administration is designed to
target RPE cells underlying surviving photoreceptor cells as
demonstrated structurally by OCT scanning and functionally by
perimetry. Exploiting the natural plane of cleavage between the
RPE and overlying photoreceptors, vector suspension is injected
through the neurosensory retina via one or more small
retinotomies into this potential space, causing separation of the
cell layers. Active absorption of ﬂuid by RPE cells promotes their
transduction by vector particles, and the temporary retinal
detachment typically resolves spontaneously within 48 h.
Although even temporary detachment of the retina can adversely
affect retinal structure and function, the relatively modest risk of
harm to vision can be justiﬁed by the potential for beneﬁt from
restoration of retinoid metabolism. The extent of the retinal area
targeted deserves careful consideration; given that non-cell-
autonomous mechanisms can contribute to retinal cell death,
widespread administration to surviving retina may help protect
against degeneration. Although the sites for injection retinotomies
can be precisely selected, the distribution of vector suspension
within the subretinal space is strongly inﬂuenced by variable
regional resistance to retinal detachment. Given that the balance
of risks relating to subfoveal delivery of vector in RPE65-deﬁciency
appears to be less favourable8,17 delivery techniques that
minimize the height and duration of any foveal detachment
may be desirable, possibly through the use of multiple injection
retinotomies.
AAV2/5-OPTIRPE65 improves retinal function in vivo in mice at
titres around 300-fold lower than the original AAV2/2-hRPE65
vector. The impact of codon optimisation for human cells is
expected to improve this 6-fold further in humans, providing up to
1800-fold greater potency. When compared with an AAV2/2-CBA.
hRPE65 vector, cautious estimates of differences suggest that the
AAV2/5-OPTIRPE65 vector uses a promoter as effective as the CBA
promoter, a coding sequence 7-fold more effective, an AAV
serotype about 4-fold more effective (Figure 2c) and a vector dose
6-fold higher. As these relative efﬁcacies are independent, the
overall difference in RPE65 production can be conservatively
estimated at 150-fold greater efﬁciency than an AAV2/2 vector
carrying hRPE65 driven by a CBA promoter. We hypothesize that,
in humans affected by LCA2, AAV2/5-OPTIRPE65 will provide
higher levels of RPE65 protein than either AAV2/2-hRPE65 or
AAV2/2.CBA.hRPE65, leading to greater and more sustained
beneﬁt.
MATERIALS AND METHODS
Cell lines, plasmid transfection and viral transduction
Mouse ﬁbroblasts (3T3) and human embryonic kidney cells (293Ts)
were maintained with DMEM medium supplemented with 10%
fetal bovine serum. The human embryonic stem cell line H9 and
induced pluripotent stem cell line IRM90-4 (Wicell) were
maintained under feeder free conditions on E8 and geltrex coated
six well plates and tested for mycoplasma infection monthly.
Differentiation of stem cells to RPE cell fate was achieved using a
multi-step protocol adapted from previous published
protocols18,19 (Supplementary Methods). For plasmid transfec-
tions, 100 000 cells were plated the day before on 24 well plates.
One microgram of corresponding plasmids was transfected
using Lipofectamine 2000 according to manufacturer’s directions
Figure 4. Dose-response of the AAV2/5-OPTIRPE65 on retinal
function as demonstrated by electroretinography. Rpe65-deﬁcient
mice were injected with AAV2/5-OPTIRPE65 in one eye and with
AAV2/2-hRPE65 in the contralateral eye at increasing titres. Retinal
activity in the animals was assessed by dark-adapted electroretino-
graphy at 3 cd/m2. The graph shows average scotopic b-wave
amplitudes (mean± s.d.) at 6 weeks post-treatment, when both
vectors had reached peak expression. n= 4.
Figure 5. AAV2/5-OPTIRPE65 mediates physiological expression
levels of RPE65 mRNA in the mouse retina. Whole retina lysates
from WT mice 6 weeks following injection with AAV2/5-OPTIRPE65
or AAV2/2-hRPE65 were used for quantitative real-time PCR (qPCR).
Absolute quantiﬁcation of total mRNA-derived cDNA was performed
for human RPE65 transcripts, OptiRPE65 transcripts and endogenous
murine Rpe65 transcripts (mean± s.d.). Dose: 4 × 109 vg per eye,
n= 4.
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(Life Technologies, Paisley, UK) and cells were analysed 48 h after
transfection. For transduction of ~ 2 × 106 iPS-derived RPE cells,
1.2 × 1011 vg of AAV2/5-NA65p.GFP, AAV2/5-CMV.GFP or AAV2/2-
CMV.GFP were added to each well.
Virus preparation
AAV backbone plasmid constructs were packaged into AAV2,
AAV5 and AAV8 to generate the recombinant AAV viral vectors
required for this study (Supplementary Figure.S1). Recombinant
vectors were produced through a triple transient transfection
method using published methods20 (Supplementary methods).
Animals and subretinal injections
The Rpe65 knockout mice (Rpe65rd12/rd12) were purchased from
Jackson Laboratories (US) and WT mice (C57BL/6J) were pur-
chased from Harlan Laboratories (Blackthorn, UK). WT rabbits
(New Zealand Whites) were purchased from Envigo (Hundingdon,
UK). Young adult (6–10 weeks) animals were used throughout. WT
animals were all females, while Rpe65−/− were mixed sex. Animals
were maintained under cyclic light (12 h light–dark) conditions. All
experiments were approved by the local Institutional Animal Care
and Use Committees (UCL, London, UK) and conformed to the
guidelines on the care and use of animals adopted by the Society
for Neuroscience and the Association for Research in Vision and
Ophthalmology (Rockville, MD, USA). Subretinal administration of
vectors was performed as previously described20 (Supplementary
methods). Eyes were assigned as treated and (contralateral)
control eyes using randomisation software (https://www.randomi
zer.org/). After the injection procedure, investigators were masked
regarding the eye receiving treatment during the in vivo stages.
Four eyes from 4 animals were treated for efﬁcacy assessments,
based on a power calculation to detect a minimum 10-fold
difference in potency.
Immunostaining
iPS-derived RPE cells were ﬁxed on 4% Paraformaldehyde for
immunocytochemistry analysis 7 days post virus transduction.
Cells were blocked in 5% goat serum and 1% bovine serum
albumin in PBS containing 0.1% Triton-X100. Primary rabbit anti-
ZO-1 antibody (Life technologies, Paisley, UK) was used at 1:200
and rabbit anti-phalloidin TRITC (Sigma-Aldrich, Dorset, UK) was
used at a concentration of 1:500. Primary antibodies were
incubated overnight at 4 °C in blocking solution. Secondary
antibody staining was performed for 2 h at room temperature
followed by PBS washing and counterstaining with 4′,6-diamidino-
2-phenylindole.
RNA extractions and cDNA preparation
Enucleated eyes (Figures 1 and 5), RPE/choroid dissections
(Supplementary Figure.S2) or cell pellets (Figure 3, Supple-
mentary Figure S4) were obtained and total mRNA was extracted
using an RNeasy mini Kit (Qiagen, Crawley, UK). One microgram of
total RNA was used to generate cDNA using the QuantiTect
Reverse Transcription kit (Qiagen, Crawley, UK). According to
manufacturer’s directions, the conversion of RNA to cDNA should
be at a rate of 1:1.
Figure 6. Structural and functional assessments of WT mouse and rabbit retinas following subretinal injection of AAV2/5-OPTIRPE65. ERG
responses and retinal thickness measurements of eyes injected with AAV2/5-OPTIRPE65 (n= 10 for mice, n= 9 for rabbits) and untreated
control eyes (n= 4 for mice, n= 9 for rabbits) of young adult WT mice. Mean± s.d. scotopic (at 0.01 Cds per m2) and photopic (at 10 Cds per
m2) ERG b-wave amplitudes of mice retinas at 9 months (a) or rabbit retinas at 8 weeks (d) are shown. The Y axis denotes μV values of electrical
conductivity. Dose: 4 × 109 vg per eye in mice, 2 × 1011 vg per eye in rabbits. Mean± s.d. photoreceptor cell layer thickness measurements from
treated and untreated eyes are shown (b for mice, e for rabbits). Representative images of mouse (c) and rabbit (f) retinal morphology: GCL,
ganglion cell layer; INL, inner nuclear layer; outer nuclear layer; IS/OS, inner segments/outer segments; RPE.
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qPCR
Real-time quantitative RT-PCR (qPCR) was performed with a
commercial thermal cycler (7900HT; Applied Biosciences, Foster
City, CA). All reagents were obtained from Roche Diagnostics
(Burgess Hill, UK). The technique was based on FAM-labelled
hydrolysis probes (Roche Diagnostics, Burgess Hill, UK), and
primers were designed for speciﬁc probe-binding regions using
the Roche Universal Probe Library (see Supplementary Methods
for details). For absolute quantiﬁcation of murine, human and
human codon-optimized RPE65 genes, amplicons speciﬁc to each
reaction were used to prepare serial dilution standard curves
ranging from 109 to 102 molecules. The standard curve was used
for sample molecule number interpolation.
Electroretinographic analysis
ERGs were recorded from both eyes of Rpe65− /− mice, C57BL6/J
WT mice and New Zealand White WT rabbits. All animals were
dark adapted overnight before ERG recordings under anaesthesia.
The pupils were dilated with a drop of Minims Tropicamide 1%
(Bausch & Lomb/Chauvin Pharmaceuticals, Essex, UK). Midline
subdermal ground and mouth reference electrodes were ﬁrst
placed, followed by eye electrodes that were allowed to
lightly touch the corneas. A drop of Viscotears 0.2% liquid gel
(Dr Robert Winzer Pharma/OPD Laboratories, Watford, UK) was
placed on top of the electrodes to keep the corneas moistened
during recordings. Scotopic and photopic ERGs were recorded
with commercially available equipment (Espion E2; Diagnosys,
Lowell, MA) using published methods20 (see Supplementary
Methods for details).
Statistical analysis
Experimental results were analysed using Student t-test (Figures
2, 3 and 6 and S2) or One-way analysis of variance (Figure 5),
including D’Agostino and Pearson normality tests and Bartlett’s test
for equal variance. All analyses were performed 2-sided. Graphs show
means± s.e.m. N-numbers and P-values are reported in the ﬁgure
legends. N-numbers were chosen, based on power calculations.
No animals or samples were excluded from analysis.
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